Identification of PD-L1-related biomarkers for selecting gastric adenocarcinoma patients for PD-1/PD-L1 inhibitor therapy
Abstract PD-1/PD-L1 inhibitors have been used to treat gastric cancer, and PD-L1 expression has been identified as a biomarker for predicting the effectiveness of immunotherapy in the treatment of gastric cancer. However, PD-L1 expression prediction for immunotherapy response is inaccurate, and impr...
Saved in:
| Main Authors: | Bo-Ya Li, Hui-Ling Li, Fei-Er Zeng, Xuan-Yu Luan, Bi-Qing Liu, Zhi-Zhou Wang, Lan Zhang, Xian-Zhe Dong |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-05-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02515-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Identification of lncRNA dual targeting PD-L1 and PD-L2 as a novel prognostic predictor for gastric cancer
by: Li-Na Zhang, et al.
Published: (2024-10-01) -
Cost-effective analysis of sugemalimab plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma with PD-L1 CPS ≥5
by: Yalan Zhang, et al.
Published: (2025-08-01) -
Methionine restriction promotes the polarization of macrophages towards M1 and the immunotherapy effect of PD-L1/PD-1 blockades by inhibiting the secretion of MIF by gastric carcinoma cells
by: Lin Xin, et al.
Published: (2025-01-01) -
PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution
by: Ryohei Kondo, et al.
Published: (2025-05-01) -
Clinical importance of VEGFC and PD‐L1 co‐expression in lung adenocarcinoma patients
by: Tingting Qin, et al.
Published: (2020-05-01)